| abstract |
The present invention relates to compounds of formula (I) wherein R < 1 > Formula I In this formula, R < 1 > is hydrogen or lower alkyl; R 2 is hydrogen or lower alkyl, optionally substituted with one or more halogens, lower alkyl, halogen substituted with halogen, lower alkoxy, lower alkoxy substituted with halogen, cyano, S-lower alkyl, S (O) O) 2 -lower alkyl, C (O) -lower alkyl or C 3-6 -cycloalkyl; R 3 is hydrogen, halogen, lower alkyl, substituted by halogen, lower alkyl, substituted by lower alkoxy, halo-lower alkoxy, cyano, S- lower alkyl, S (O) - lower alkyl, S (O) 2 - lower Alkyl, C (O) -lower alkyl or C 3-6 -cycloalkyl; R < 4 > is hydrogen or lower alkyl; Is phenyl or pyridinyl, wherein the N-atom may be in a different position; X is a bond or -CH (CF 3) - and; Ar is aryl or heteroaryl optionally substituted with one or more R < 3 & gt ;. The compounds of formula I have been found to have good affinity for the microamine related receptors (TAAR), in particular TAAR1. Such compounds are useful in the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress related disorders, psychotic disorders such as schizophrenia, neurological disorders such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, Hypertension, substance abuse or metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, energy expenditure or assimilation disorders, body temperature homeostatic disorder or dysfunction, sleep or circadian rhythm disorders, or cardiovascular disorders Can be used. |